SEC Company Response from Oncotelic Therapeutics, (OTLC) — May 28, 2021
Oncotelic Therapeutics, Inc.
Date: May 28, 2021 · CIK: 0000908259 · Accession: 0001493152-21-013140
AI Filing Summary & Sentiment
File numbers found in text: 333-256448
Letter
RE: Oncotelic Therapeutics, Inc. (CIK: 0000908259)
May 28, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Attn: Dillon Hagius
Registration Statement No. 333-256448 on Form S-1 (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Oncotelic Therapeutics, Inc. hereby requests the acceleration of the effective date of the above referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time, June 2, 2021, or as soon thereafter as practicable.
Oncotelic Therapeutics, Inc.
By:
/s/ Vuong Trieu
Name: Vuong Trieu
Title: Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
May
28, 2021
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
DC 20549
Attn:
Dillon Hagius
RE:
Oncotelic
Therapeutics, Inc. (CIK: 0000908259)
Registration
Statement No. 333-256448 on Form S-1 (the “Registration Statement”)
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as
amended (the “Securities Act”), Oncotelic Therapeutics, Inc. hereby requests the acceleration of the effective date of the
above referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time, June 2, 2021, or as soon thereafter
as practicable.
Oncotelic Therapeutics, Inc.
By:
/s/
Vuong Trieu
Name:
Vuong
Trieu
Title:
Chief
Executive Officer